Ashley McKinney
Family · Spartanburg, SCNPI 1194372318
Payments from drug & device makers
Across 863 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biogen$1K
- Teva Pharmaceuticals USA, Inc.$889
- Neurocrine Biosciences, Inc.$748
- Acadia Pharmaceuticals Inc$663
- EMD Serono, Inc.$626
- plus $10K from 48 others
What the payments were for
- Food & beverage$15,40298%
- Education$3192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$126
How this compares
$15,721 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 29 | $251,531 |
| RebifInterferon Beta-1a/Albumin | 23 | $239,406 |
| BetaseronInterferon Beta-1b | 13 | $127,040 |
| PlegridyPeginterferon Beta-1a | 13 | $107,456 |
| NuplazidPimavanserin Tartrate | 19 | $97,792 |
| TecfideraDimethyl Fumarate | 11 | $96,567 |
| Nurtec OdtRimegepant Sulfate | 57 | $77,081 |
| CopaxoneGlatiramer Acetate | 13 | $75,857 |
| AustedoDeutetrabenazine | 12 | $62,969 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $49,185 |
| Glatiramer Acetate | 14 | $46,658 |
| Emgality PenGalcanezumab-Gnlm | 52 | $43,907 |
| NamzaricMemantine Hcl/Donepezil Hcl | 30 | $30,402 |
| UbrelvyUbrogepant | 17 | $26,034 |
| Dihydroergotamine Mesylate | 11 | $23,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Plegridy, Tecfidera | $1,254 | $455,55453 claims |
| EMD Serono, Inc.Rebif | $626 | $239,40623 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo | $889 | $138,82525 claims |
| Acadia Pharmaceuticals IncNuplazid | $663 | $97,79219 claims |
| AbbVieNamzaric, Ubrelvy, Qulipta, Botox | $1,908 | $96,77277 claims |
| PfizerNurtec Odt, Lyrica | $560 | $87,60373 claims |
| Kyowa Kirin, Inc.Nourianz | $238 | $22,44112 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $117 | $7,94312 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $271 | $5,18860 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Spartanburg
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.